A citation-based method for searching scientific literature

Adriana Sánchez-García, Mario Simental-Mendía, Juan Manuel Millán-Alanís, Luis E Simental-Mendía. Pharmacol Res 2020
Times Cited: 4







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100

SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids.
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios Filippatos, Theodora Dimitriou, Moses Elisaf. Expert Opin Drug Metab Toxicol 2018
18
75

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
75

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
75

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
256
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
856
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50


Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
63
50


Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
878
25

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
S Matthijs Boekholdt, Benoit J Arsenault, Samia Mora, Terje R Pedersen, John C LaRosa, Paul J Nestel, R John Simes, Paul Durrington, Graham A Hitman, K M A Welch,[...]. JAMA 2012
448
25

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.
B V Howard, D C Robbins, M L Sievers, E T Lee, D Rhoades, R B Devereux, L D Cowan, R S Gray, T K Welty, O T Go,[...]. Arterioscler Thromb Vasc Biol 2000
170
25

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman,[...]. Cardiovasc Diabetol 2014
121
25

PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
Robert M Stoekenbroek, John J P Kastelein, Roeland Huijgen. BMC Med 2015
22
25

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
Jordan Fulcher, Rachel O'Connell, Merryn Voysey, Jonathan Emberson, Lisa Blackwell, Borislava Mihaylova, John Simes, Rory Collins, Adrienne Kirby, Helen Colhoun,[...]. Lancet 2015
628
25

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
124
25

Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review.
Ranjan Dahal, Yogesh Acharya, Debabrata Mukherjee. Cardiovasc Hematol Disord Drug Targets 2020
1
100

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
535
25



Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism.
François Briand, Eric Mayoux, Emmanuel Brousseau, Noémie Burr, Isabelle Urbain, Clément Costard, Michael Mark, Thierry Sulpice. Diabetes 2016
58
25



Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.
Lorraine Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T Eurich, Lori MacCallum, Baiju R Shah, Scot Simpson, Peter A Senior. Can J Diabetes 2020
8
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25



Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
Yihai Liu, Jiamin Xu, Mingyue Wu, Biao Xu, Lina Kang. Lipids Health Dis 2021
3
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
383
25

Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition.
Debapriya Basu, Lesley-Ann Huggins, Diego Scerbo, Joseph Obunike, Adam E Mullick, Paul L Rothenberg, Nicholas A Di Prospero, Robert H Eckel, Ira J Goldberg. Arterioscler Thromb Vasc Biol 2018
28
25

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
5
25

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016
98
25


The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Matthias Kern, Nora Klöting, Michael Mark, Eric Mayoux, Thomas Klein, Matthias Blüher. Metabolism 2016
50
25

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
5
25

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
589
25

The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
Kristien E C Bouter, Erik J M van Bommel, Hans Jansen, Dewi van Harskamp, Henk Schierbeek, Mariëtte T Ackermans, Mireille J Serlie, Alinda W M Schimmel, Max Nieuwdorp, Geesje M Dallinga-Thie,[...]. Diabetes Obes Metab 2020
2
50

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Sci Rep 2019
13
25

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
204
25


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12
25

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
Yi-Chou Hou, Cai-Mei Zheng, Tzung-Hai Yen, Kuo-Cheng Lu. Int J Mol Sci 2020
3
33

JAK inhibition in the treatment of diabetic kidney disease.
Frank C Brosius, Katherine R Tuttle, Matthias Kretzler. Diabetologia 2016
57
25

Osmotically inactive skin Na+ storage in rats.
Jens Titze, Rainer Lang, Christoph Ilies, Karl H Schwind, Karl A Kirsch, Peter Dietsch, Friedrich C Luft, Karl F Hilgers. Am J Physiol Renal Physiol 2003
136
25

Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.
Tao Yuan, Shixuan Liu, Yingyue Dong, Yong Fu, Yan Tang, Weigang Zhao. Diabetol Metab Syndr 2020
1
100

Salt Sensitivity and Hypertension: A Paradigm Shift from Kidney Malfunction to Vascular Endothelial Dysfunction.
Hoon Young Choi, Hyeong Cheon Park, Sung Kyu Ha. Electrolyte Blood Press 2015
27
25

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
Simon A Hawley, Rebecca J Ford, Brennan K Smith, Graeme J Gowans, Sarah J Mancini, Ryan D Pitt, Emily A Day, Ian P Salt, Gregory R Steinberg, D Grahame Hardie. Diabetes 2016
136
25



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.